Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: Results of a 12-month multicenter, open-label, prospective study

被引:11
作者
Vogt, B. [1 ]
Antoniadis, A. [1 ]
Klinger, M. [1 ]
Vitko, S. [1 ]
机构
[1] Univ Bern, Inselspital, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland
关键词
D O I
10.1016/j.transproceed.2006.02.125
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Enteric-coated mycophenolate sodium (EC-MPS) has been developed as an alternative formulation of mycophenolate acid aiming for improved gastrointestinal (GI) tolerability. This 12-month, open-label, multicenter, prospective study investigated the efficacy and tolerability of EGMPS (720 mg twice a day) given in combination with cyclosporine microemulsion (CsA-ME) in de novo renal transplant recipients (n = 140). The efficacy evaluation was the incidence of treatment failure (defined as biopsy-proven acute rejection [BPAR], graft loss, or death) after 6 and 12 months of treatment. The incidences of treatment failure, BPAR, and graft loss were comparable at 6 and 12 months (18.6% vs 22.1%, 15.7% vs 19.3%, and 1.4% vs 2.1%, respectively). Renal function at 6 and 12 months (creatinine clearance) was 60.6 +/- 19.8 mL/min and 63.2 +/- 27.1 mL/min, respectively. EC-MPS was generally well tolerated; 95.9% of the reported GI adverse events (AEs) were rated as mild or moderate. The rate of EGMPS dose reduction was 26.4%; 4.3% were due to GI AEs. The rate of EGMPS dose interruption was 10%; 2.1% were due to GI AEs. In summary, EGMPS given in combination with CsA-ME demonstrates good efficacy and tolerability in de novo renal transplant recipients.
引用
收藏
页码:1301 / 1306
页数:6
相关论文
共 23 条
  • [1] Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets:: Interim results of a Multicenter Latin American study
    Abbud, M
    Girón, F
    Hernández, E
    Juarez, F
    Liendo, C
    Novoa, P
    Toledo, M
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (06) : 1647 - 1649
  • [2] Adverse gastrointestinal effects of mycophenolate mofetil - Aetiology, incidence and management
    Behrend, M
    [J]. DRUG SAFETY, 2001, 24 (09) : 645 - 663
  • [3] Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study
    Budde, K
    Curtis, J
    Knoll, G
    Chan, L
    Neumayer, HH
    Seifu, Y
    Hall, M
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (02) : 237 - 243
  • [4] BUDDE K, 2005, TRANSPL P, V37, P921
  • [5] Chan L, 2005, NEPHROLOGY, V10, pA215
  • [6] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [7] GRINYO J, 1995, LANCET, V345, P1321
  • [8] The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
    Hale, MD
    Nicholls, AJ
    Bullingham, RES
    Hené, R
    Hoitsma, A
    Squifflet, JP
    Weimar, W
    Vanrenterghem, Y
    Van de Woude, FJ
    Verpooten, GA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) : 672 - 683
  • [9] Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil
    Hardinger, KL
    Brennan, DC
    Lowell, J
    Schnitzler, MA
    [J]. TRANSPLANT INTERNATIONAL, 2004, 17 (10) : 609 - 616
  • [10] Keown P, 1996, TRANSPLANTATION, V61, P1029